Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 5/20 | 0.70 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18906966 | 0.93 | ODC1 (0.62) | ODC1PTPN1PDE5AKDM4ECYP3A4 | |
| SCHEMBL16259003 | 0.87 | ODC1 (0.54) | ODC1PTPN1PDE5AKDM4ECYP3A4 | |
| SCHEMBL16694477 | 0.72 | ODC1 (0.77) | ODC1PTPN1KDM4ECYP3A4USP2 | |
| SCHEMBL24305496 | 0.71 | MAPT (0.60) | PTPN1PDE5AMEN1MAPTKMT2A | |
| SCHEMBL11911698 | 0.70 | CYP3A4 (0.79) | ODC1PTPN1KDM4ECYP3A4HSD17B10 | |
| SCHEMBL24305197 | 0.69 | HSP90AA1 (0.46) | ODC1PTPN1MEN1MAPTKMT2A | |
| SCHEMBL20960789 | 0.69 | HSD17B1 (0.61) | ODC1PTPN1CYP3A4TDP1HSD17B1 | |
| Lupinifolinol SCHEMBL6668491 | 0.67 | PTPN1 (0.50) | ODC1PTPN1PDE5AKDM4ECYP3A4 | |
| Eriosemaone A SCHEMBL31753876 | 0.66 | IDO1 (0.73) | ODC1PTPN1MEN1MAPTKMT2A | |
| SCHEMBL31441209 | 0.66 | ODC1 (0.74) | ODC1PTPN1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974766-B2 | Prenylated isoflavones for treatment of subjects with multidrug-resistant cancer | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (MO) | 2018-05-22 | — | — | US | disclosed |
| US-9974766-B2 | Prenylated isoflavones for treatment of subjects with multidrug-resistant cancer | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (MO) | 2018-05-22 | — | — | US | disclosed |
| US-20170151212-A1 | PRENYLATED ISOFLAVONES FOR TREATMENT OF SUBJECTS WITH MULTIDRUG-RESISTANT CANCER | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170151212-A1 | PRENYLATED ISOFLAVONES FOR TREATMENT OF SUBJECTS WITH MULTIDRUG-RESISTANT CANCER | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151212-A1 | PRENYLATED ISOFLAVONES FOR TREATMENT OF SUBJECTS WITH MULTIDRUG-RESISTANT CANCER | ABCB1, ABCC1, ABCB11 | ODC1 4081/4885PTPN1 3874/4885PDE5A 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.